Mirum Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(25,279) | $(30,130) |
| Reconciliation of net loss to net cash provided by (used in) operating activities: | ||
| Stock-based compensation | 11,450 | 8,561 |
| Depreciation and amortization | 5,664 | 1,337 |
| Inventory reserves and firm commitment losses | 237 | — |
| Costs recognized on sale of acquired inventory | 2,209 | — |
| Amortization of debt discount and offering costs | 414 | — |
| Non-cash interest expense related to the revenue interest liability | — | 4,242 |
| Unrealized foreign exchange gain | (1,734) | — |
| Other | 518 | (153) |
| Change in operating assets and liabilities: | ||
| Accounts receivable | 12,969 | (667) |
| Prepaid and other current assets | 918 | (40) |
| Inventory | (3,173) | (778) |
| Other assets | 11 | 285 |
| Accounts payable, accrued expenses and other liabilities | 11,277 | (1,212) |
| Operating lease liabilities | (269) | (219) |
| Net cash provided by (used in) operating activities | 15,212 | (18,774) |
| Investing activities | ||
| Purchase of investments | — | (22,444) |
| Proceeds from maturities of investments | — | 64,500 |
| Purchase of property and equipment | (13) | (41) |
| Payments made for additions to intangible assets | — | (15,000) |
| Net cash (used in) provided by investing activities | (13) | 27,015 |
| Financing activities | ||
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | — | 14,480 |
| Proceeds from issuance of common stock pursuant to equity plans | 1,205 | 1,390 |
| Payments on revenue interest liability | — | (2,883) |
| Net cash provided by financing activities | 1,205 | 12,987 |
| Effect of exchange rate on cash, cash equivalents and restricted cash equivalents | 113 | 188 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 16,517 | 21,416 |
| Cash, cash equivalents and restricted cash equivalents at beginning of period | 286,326 | 128,003 |
| Cash, cash equivalents and restricted cash equivalents at end of period | $302,843 | $149,419 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows paid for operating lease | $289 | $262 |
| Cash paid for income taxes | $139 | $— |
| Non-cash operating, investing and financing activities: | ||
| Accrued milestone payments classified as intangible assets, net | $10,000 | $— |
| Increase (decrease) of inventory purchases included in accounts payable and accrued liabilities | $(1,731) | $103 |
| Decrease in ROU assets and lease liabilities due to lease modification | $723 | $— |
| Stock-based compensation capitalized to inventory | $214 | $167 |
| Issuance of common stock in connection with settlement of Contingent Milestone liability | $— | $4,292 |
| Deferred offering costs in accrued liabilities | $— | $240 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.